Evolocumab
Class
Hypolipidemic agents
Subclass
Anti-PCSK9 monoclonal antibodies
Substance name
Evolocumab
Brand names
Repatha®
Common formulations
Solution for injection
Dosage and administration
Adults patients
Treatment
Heterozygous familial hypercholesterolemia
Homozygous familial hypercholesterolemia
Primary hyperlipidemia
Adjunctive treatment
Adjunctive treatment for homozygous familial hypercholesterolemia
Prevention
Prevention of cardiovascular events in patients with CVD
Indications for use
Labeled indications
Adults
Children
Safety risks
Contraindications
Hypersensitivity to evolocumab or its components
Warnings and precautions
Drug hypersensitivity reaction
Specific populations
Renal impairment
eGFR 0-90 mL/min/1.73 m²
Renal replacement therapy
Any modality
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B1
Breastfeeding
Use only if benefits outweigh potential risks.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource